(For more market insights, including options activity, click onSTXNEWS/US; for the Day Ahead newsletter http://link.reuters.com/mex49s; ; for the Morning News Call newsletter, http://link.reuters.com/nex49s)Wall Street was set to open lower on Wednesday as investorsshifted their focus from the Turkish central bank's boldinterest-rate hike to the U.S. Federal Reserve's impendingdecision later in the day on its monthly bond-buying program.Dow Jones industrial average futures were down 0.75percent at 15,757, S&P 500 futures were down 0.96 percentat 1,771.1 and Nasdaq 100 futures were down 0.99 percentat 3,466.25.
The planemaker forecast 2014 results below analysts' averageestimates as it expects margin to fall in both its majorsegments.
** DOW CHEMICAL CO, Tuesday close $43.06, +5.09 pctpremarket
The profit and largest U.S. chemical maker by sales reporteda better-than-expected quarterly tripled its share buybackprogram to $4.5 billion, joining rival DuPont inincreasing shareholder returns amid investor activism.
Vringo said a U.S. court ordered post-judgment royalty rateof 6.5 percent against the internet search giant for continuedand willful patent infringement.
The U.S. refiner said its fourth-quarter profit rose, helpedby stronger results in its transportation and processing andchemicals businesses.
The company reported a higher quarterly profit as risingticket prices bolstered revenue. The New York-based carriercited "strong" revenue trends for the current period but addedflight cancellations this month in wake of unfavorable weatherin the U.S. Northeast would hurt first quarter results.
** TUPPERWARE BRANDS CORP, Tuesday close$83.77, -6.89 pct premarket
The kitchen storage container maker forecast aweaker-than-expected profit for 2014 after its fourth-quarterresults missed market estimates due to a 5 percent fall in salesin its established markets such as Germany, Canada and theUnited States.
The company said it would present preliminary findings froma mid-stage study of its drug to treat castration resistantprostate cancer at a medical meeting in San Francisco onThursday.
The drugmaker said it expects to report fourth-quarterrevenue of about $31.9-$32.4 million, beating market estimates,helped by strong growth of its anti-inflammatory drug Rayos andarthritis drug Duexis.
Analysts had expected fourth-quarter revenue of $27.4million, according to Thomson Reuters I/B/E/S.
** FREESCALE SEMICONDUCTOR LTD, Tuesday close$15.3, +13.07 pct premarket
The company, which makes chips for cars and machinery, onTuesday forecast current-quarter revenue above analystsestimates.
Topeka Capital Markets analyst Suji De Silva expectscontinued growth in Freescale's microcontrollers business,multicore network processors and further deployment in the Chinawireless infrastructure market. De Silva raised his price targeton the company's stock to to $23 from $19.
Needham & Co LLC raised the stock's rating to "strong buy"from "buy," and raised the price target to $25 from $20.
The telecom company's fourth-quarter wireless subscribergrowth and its free cash flow target lagged well behind analystestimates. Chief Executive Randall Stephenson said a U.S. spyingscandal was hurting the company's business.
At least one brokerage cut its rating on the stock.
** VODAFONE GROUP PLC, Tuesday close $37.17, -1.24pct premarket
Shareholders of both Vodafone and Verizon (NYSE: VZ - news) approvedVerizon's $130 billion takeover of their Verizon Wirelessventure on Tuesday, paving the way for the third-biggest deal incorporate history.
The company's online ad prices slid again in the fourthquarter and Alibaba, the Chinese e-commerce giant in which itowns a big stake, saw revenue growth decelerate from its recentrip-roaring pace. Overall revenue fell 6 percent in the lastthree months of the year, the company said.
At least two brokerages cut their price targets on thestock.
** SOTHEBY'S, Tuesday close $48.88, +4.09 pctpremarket
The auction house will pay investors a special dividend andbuy back shares, months after activist investor Daniel Loebcalled for a management shakeup.
The company's drug for advanced prostate cancersignificantly delayed progression of the disease and extendedsurvival in a large, late stage study of patients who had notyet received chemotherapy, likely paving the way for an expandedapproval of the medicine.
The videogame publisher raised its full-year earningsforecast for the year, driven by strong cost control measures.It now sees non-GAAP income of $1.30 per share, compared withits previous forecast of $1.22.
At least two brokerages raised their price targets on thestock.
** HESS CORP, Tuesday close $76.8, -1.30 pctpremarket
The company reported a quarterly profit well below WallStreet expectations as oil and natural gas production lagged dueto instability in Libya and maintenance in the U.S. Gulf ofMexico.
The industrial automation company lifted the lower end ofits 2014 forecast after reporting a 23 percent jump infirst-quarter profit due to sales increases in Europe, AsiaPacific and the United States.
** EMC CORP, Tuesday close $25.38, -0.91 pctpremarket
The world's largest data storage equipment maker, forecastcurrent-quarter results below analysts' estimates.
The company said its new, high-profile oral multiplesclerosis drug Tecfidera had sales of $398 million in the fourthquarter, easily exceeding estimates for a third successivequarter and keeping it on track to top $1 billion in its firstyear on the market.
The largest industrial gas supplier in the Americas raisedits dividend by 8 percent and set another $1.5 billion sharebuyback plan, after its quarterly profit rose due to strongsales and acquisitions.
the second-largest U.S. health insurer reported a lowerquarterly profit as it took a charge for the sale of its contactlens business and consumers increased their use of medicalservices as they faced the loss of health plans at the end of2013.
** CANADIAN PACIFIC RAILWAY, Tuesday close$141.86, +0.10 pct premarket
Canada's second largest railway reported a five-foldjump in fourth-quarter profit, as freight revenue rose 7percent.
** MARATHON PETROLEUM CORP, Tuesday close$83.17, +0.59 pct premarket
The third-largest stand-alone U.S. refining company posted a17 percent drop in quarterly profit on Wednesday due toshrinking crude discounts and rising maintenance costs.
** OMEROS CORP, Tuesday close $11.23, +9.26 pctpremarket
The company said data from a mid-stage study of itscognitive disorder drug showed that the drug's tolerability wasnot affected when used in combination with antipsychoticmedicines. Omeros (Frankfurt: 3O8.F - news) said the drug could be developed as a singletherapy or be tested along with other antipsychotic medicines infurther studies on schizophrenia patients.
The air ambulance service provider estimated fourth-quarterearnings below analysts' expectations and said it would incur$2.4 million in pretax charges during. The company also saidpatient transports in the quarter decreased compared with theprior year.
The company reported fourth-quarter results above analysts'estimates, helped by higher-than-expected international sales ofits neurology and newborn care products. Natus also raised its2014 adjusted earnings forecast to the range of $1.14-$1.18 pershare from the $1.12-$1.16 it earlier expected.
The pawn and payday lender reported a stronger-than-expectedfirst-quarter profit helped by higher merchandise sales in theUnited States and Canada. Merchandise sales rose 12 percent to$105.6 million for the quarter ended Dec. 31.
The virtualization software maker reported a slightlybetter-than-expected quarterly profit helped by higher revenuefrom license sales.
At least four brokerages raised their price targets on thestock.
The computer security specialist topped fourth-quarterprofit and revenue forecasts and said it sees growth continuinginto 2014 on strong demand for high-end products that protectdata centers.
The world's biggest biotechnology company on Tuesdayreported a quarterly profit that beat Wall Street forecasts asit gained full control of its blockbuster rheumatoid arthritisdrug Enbrel and recorded solid growth in sales of newerproducts. The company also announced another positive resultfrom a late-stage study of its high-profile experimentalcholesterol drug, evolocumab.
At least four brokerages raised their price targets on thestock.
-6.59** QUALCOMM INC, Tuesday close $71.99, +0.00pct premarket
The world's biggest cellphone chip maker may be hit with arecord fine exceeding $1 billion in a Chinese antitrust probe,raising the specter of harsh penalties for foreign firms facingan increasingly aggressive regulator.
** TEVA PHARMACEUTICAL INDUSTRIES, Tuesday close$44.1, +2.27 pct premarket
Teva's shares open higher after the company said U.S. regulators approved its three-times-a-week multiplesclerosis drug Copaxone. The world's largest generics drugmakerhas been banking on a three-times-a-week version of Copaxoneahead of possible competition from generic rivals of the drugthis year. (Compiled by Natalie Grover in Bangalore; Editing by JoyjeetDas (Shenzhen: 002421.SZ - news) )
- Company Earnings
- Investment & Company Information